Related Experiment Video
Updated: Jul 8, 2026

The use of SC1 (Pluripotin) to Support mESC Self-renewal in the Absence of LIF
Published on: November 18, 2009
SLFN11 binds DDX1 to counteract human mesenchymal stem/stromal cell senescence through inhibition of mTOR/eIF4E
Xin-Xin Zhu1, Yi Luo1, Jin-Yan Xu2
1Institute of Medicinal Biotechnology, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan District, Zunyi, 563003, China; Guizhou Provincial Key Laboratory of Medicinal Biotechnology & Research Center for Translational Medicine in Colleges and Universities, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan District, Zunyi, 563003, China; Zunyi Municipal Key Laboratory of Medicinal Biotechnology, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan District, Zunyi, 563003, China.
Aims:
Mesenchymal stem/stromal cells (MSCs) are indispensable for cellular therapy; however, long-term in vitro expansion triggers replicative and stress-induced senescence, which undermines their stemness and therapeutic potential. This study aimed to investigate the protective effect and underlying mechanism of the Schlafen (SLFN) 11 gene against human MSC senescence in vitro and to evaluate the efficacy and safety of SLFN11-overexpressing MSCs.
Materials And Methods:
SLFN11 was overexpressed in human MSCs via lentiviral transduction. Protective effects were comprehensively assessed in replicative and stress-induced senescence models by evaluating cell cycle arrest, proliferative and clonogenic capacities, DNA damage, pluripotency, and β-galactosidase activity. Molecular interactions were elucidated through co-immunoprecipitation (Co-IP) and LC-MS/MS, whereas therapeutic efficacy was determined using a DSS-induced ulcerative colitis mouse model.
Key Findings:
SLFN11 overexpression significantly attenuated senescence by reducing DNA damage accumulation, reversing cell cycle arrest, and enhancing proliferation, clonogenicity, and stemness properties. Mechanistically, SLFN11 bound the RNA helicase DDX1 to attenuate mTOR/eIF4E signaling, thereby resisting senescence. Compared to control MSCs, SLFN11-overexpressing MSCs exhibited superior protection against ulcerative colitis, as evidenced by reduced colonic lesions, maintenance of mucosal integrity, and inhibition of proinflammatory factor secretion. SLFN11-overexpressing MSCs also showed no detectable tumorigenicity or chromosomal aberrations.
Significance:
These findings delineate a non-canonical role for SLFN11 safeguarding MSCs from senescence via the DDX1/mTOR/eIF4E axis. SLFN11-overexpressing MSCs therefore constitute a promising and safe cell therapy source, characterized by preserved pluripotency and augmented therapeutic efficacy.
Insights
Schlafen (SLFN) 11 gene protects mesenchymal stem/stromal cells (MSCs) from senescence by targeting DDX1/mTOR/eIF4E signaling. SLFN11-engineered MSCs show enhanced therapeutic efficacy and safety for cell therapy.
Area of Science:
- Cell Biology
- Stem Cell Biology
- Molecular Biology
Background:
- Mesenchymal stem/stromal cells (MSCs) are crucial for cellular therapy.
- In vitro expansion leads to MSC senescence, reducing stemness and therapeutic potential.
Purpose of the Study:
- Investigate the protective role of the Schlafen (SLFN) 11 gene against human MSC senescence.
- Elucidate the mechanism of SLFN11 in preventing senescence.
- Evaluate the efficacy and safety of SLFN11-overexpressing MSCs for therapeutic applications.
Main Methods:
- Overexpressed SLFN11 in human MSCs using lentiviral transduction.
- Assessed senescence markers, including cell cycle arrest, proliferation, DNA damage, and β-galactosidase activity.
- Utilized co-immunoprecipitation and LC-MS/MS to identify molecular interactions.
- Evaluated therapeutic efficacy in a DSS-induced ulcerative colitis mouse model.
Main Results:
- SLFN11 overexpression attenuated MSC senescence, enhancing proliferation, clonogenicity, and stemness.
- SLFN11 bound DDX1, inhibiting mTOR/eIF4E signaling to resist senescence.
- SLFN11-engineered MSCs demonstrated superior protection against ulcerative colitis in mice.
- No detectable tumorigenicity or chromosomal aberrations were observed in SLFN11-overexpressing MSCs.
Conclusions:
- SLFN11 plays a novel role in protecting MSCs from senescence through the DDX1/mTOR/eIF4E pathway.
- SLFN11-overexpressing MSCs represent a promising and safe cell source for therapy with preserved pluripotency and enhanced efficacy.
Related Concept Videos
Mesenchymal Stem Cells
Replicative Cell Senescence
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Satellite Stem Cells and Muscular Dystrophy
Abnormal Proliferation